The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal CytopeniasZhuoer Xie, Aref Al‐Kali, Alexandra N. Smith et al.|Blood|2022Cited by 6
Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies By <i>TP53</i> and <i>IDH1/2</i> Mutation: Results from the AML Real World Evidence (ARC) InitiativeOfir Wolach, Aaron D. Goldberg, Kendra Sweet et al.|Blood|2022Cited by 2
Real-world patient management practices in responders to venetoclax for newly diagnosed acute myeloid leukemia.Ofir Wolach, Aaron D. Goldberg, Pinkal Desai et al.|Journal of Clinical Oncology|2025Cited by 0